C12Y 305/04
In cyclic amidines
Official title: in cyclic amidines (3.5.4)
C12Y305/04 (In cyclic amidines) appears on 287 US grants and 787 published applications in this corpus.
Search patents in C12Y- Granted patents
- 287
- Published applications
- 787
- Assignees
- 299
- Inventors
- 1,557
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 10 | 1 |
| 2002 | 6 | 4 |
| 2003 | 0 | 1 |
| 2004 | 2 | 1 |
| 2005 | 0 | 4 |
| 2006 | 0 | 5 |
| 2007 | 2 | 1 |
| 2008 | 2 | 3 |
| 2009 | 1 | 7 |
| 2010 | 2 | 3 |
| 2011 | 2 | 5 |
| 2012 | 3 | 3 |
| 2013 | 0 | 7 |
| 2014 | 8 | 7 |
| 2015 | 4 | 22 |
| 2016 | 5 | 9 |
| 2017 | 9 | 20 |
| 2018 | 14 | 22 |
| 2019 | 9 | 41 |
| 2020 | 20 | 44 |
| 2021 | 16 | 59 |
| 2022 | 26 | 91 |
| 2023 | 34 | 95 |
| 2024 | 34 | 119 |
| 2025 | 36 | 106 |
| 2026 | 36 | 107 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12Y 305/04004Adenosine deaminase113
- C12Y 305/04005Cytidine deaminase85
- C12Y 305/04001Cytosine deaminase64
- C12Y 305/04025Gtp cyclohydrolase ii22
- C12Y 305/04002Adenine deaminase17
- C12Y 305/04016Gtp cyclohydrolase i13
- C12Y 305/04009Methenyltetrahydrofolate cyclohydrolase5
- C12Y 305/04003Guanine deaminase4
All 32 subgroupsShow fewer
- C12Y 305/04006Amp deaminase2
- C12Y 305/04014Deoxycytidine deaminase2
- C12Y 305/0401Imp cyclohydrolase1
- C12Y 305/04019Phosphoribosyl-amp cyclohydrolase1
- C12Y 305/04021Creatinine deaminase1
- C12Y 305/04023Blasticidin-s deaminase1
- C12Y 305/04026Diaminohydroxyphosphoribosylaminopyrimidine deaminase1
- C12Y 305/04007Adp deaminase0
- C12Y 305/04008Aminoimidazolase0
- C12Y 305/04011Pterin deaminase0
- C12Y 305/04012Dcmp deaminase0
- C12Y 305/04013Dctp deaminase0
- C12Y 305/04015Guanosine deaminase0
- C12Y 305/04017Adenosine-phosphate deaminase0
- C12Y 305/04018Atp deaminase0
- C12Y 305/0402Pyrithiamine deaminase0
- C12Y 305/040221-pyrroline-4-hydroxy-2-carboxylate deaminase0
- C12Y 305/04024Sepiapterin deaminase0
- C12Y 305/04027Methenyltetrahydromethanopterin cyclohydrolase0
- C12Y 305/04028S-adenosylhomocysteine deaminase0
- C12Y 305/04029Gtp cyclohydrolase iia0
- C12Y 305/0403Dctp deaminase0
- C12Y 305/04031S-methyl-5'-thioadenosine deaminase0
- C12Y 305/040328-oxoguanine deaminase0
Recent patents
- Method for modulating RNA splicing by inducing base mutation at splice site or base substitution in polypyrimidine region6 Oct 2026US 12,753,420 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- DCAS13-mediated therapeutic RNA base editing for in vivo gene therapy29 Sep 2026US 12,746,295 B2University of Massachusetts
- Adenine deaminases and compositions, systems, and methods thereof29 Sep 2026US 12,747,436 B2Profluent Bio Inc.
- Compositions comprising a CAS12I polypeptide and uses thereof29 Sep 2026US 12,747,457 B2Arbor Biotechnologies, Inc.
- Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor25 Aug 2026US 12,716,076 B2National University Corporation Kobe University
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Cas-embedded Cytidine Deaminase Ribonucleoprotein Complexes having Improved Base Editing Specificity and Efficiency8 Oct 2026US 2026/0308553 A1University of Massachusetts
- System, Kit, and Method for Continuous Directed Evolution8 Oct 2026US 2026/0308569 A1The Board of Trustees of the University of Illinois
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use1 Oct 2026US 2026/0297552 A1Life Edit Therapeutics, Inc.
Most cited
By later US patents
- RNA containing modified nucleosides and methods of use thereof353US 8,278,036 B2The Trustees of the University of Pennsylvania · 2012
- RNA containing modified nucleosides and methods of use thereof230US 8,691,966 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof222US 8,748,089 B2The Trustees of the University of Pennsylvania · 2014
- RNA containing modified nucleosides and methods of use thereof198US 8,835,108 B2The Trustees of the University of Pennsylvania · 2014
- Methods for correcting presenilin point mutations123US 9,068,179 B1President and Fellows of Harvard College · 2015